



Europäisches Patentamt  
European Patent Office  
Office européen des brevets



(11) Publication number: **0 424 064 A1**

(12)

## EUROPEAN PATENT APPLICATION

(21) Application number: **90311253.0**

(22) Date of filing: **15.10.90**

(51) Int. Cl.<sup>5</sup>: **C07D 209/52, C07C 233/52,  
C12N 1/00, C12N 9/86,  
C12P 41/00**

The applicant has filed a statement in accordance with Rule 28 (4) EPC (issue of a sample only to an expert). Accession number(s) of the deposit(s): NCIMB 40249, 40213.

(30) Priority: **16.10.89 GB 8923278  
27.10.89 GB 8924209  
17.01.90 GB 9000995**

(43) Date of publication of application:  
**24.04.91 Bulletin 91/17**

(84) Designated Contracting States:  
**AT BE CH DE DK ES FR GB GR IT LI LU NL SE**

(71) Applicant: **ENZYMATIX LTD.  
Science Park, Milton Road  
Cambridge, CB4 4WE(GB)**

(72) Inventor: **Evans, Christopher Thomas  
Stable Cottage, Fowlmere Road  
Heydon, Hertfordshire SG8 8PU(GB)  
Inventor: Roberts, Stanley Michael  
Combe Cottage, Slittercombe Lane  
Kenton, Devon EX6 8NH(GB)**

(74) Representative: **Perry, Robert Edward et al  
GILL JENNINGS & EVERY 53-64 Chancery  
Lane  
London WC2A 1HN(GB)**

(54) **Chiral compounds.**

(57) Lactamase of 1-amino-3-carboxylic acid cyclic compounds are provided in enantiomeric form, together with an enantiomer of the corresponding ring-opened amino-acid or ester, by reaction of the racemic lactam with a novel lactamase. The products are useful in the synthesis of chiral carbocyclic nucleotides.

**EP 0 424 064 A1**

## CHIRAL COMPOUNDS


Field of the Invention

This invention relates to chiral compounds having utility as intermediates in the synthesis of anti-viral agents, and to a process for their preparation.

Background of the Invention

Various 9-substituted purines are known as anti-viral and anti-neoplastic agents. One such compound, known as AZT, has been used for the treatment of AIDS. More recent examples are disclosed in EP-A-4268672, US-A-4742064, and also in GB-A-2217320 which, by way of specific illustration, describes a compound known as Carbovir (carbocyclic 2',3'-didehydro-2',3'-dideoxyguanosine). Not surprisingly, the enantiomers of such chiral compounds have different activities.


Carbovir and known analogues are prepared from the known  $\gamma$ -lactam, 2-azabicyclo[2.2.1]hept-5-en-3-one, i.e. the compound of formula



I

in which X is  $-\text{CH}_2-$ ,  $-\text{Y}-\text{Z}-$  is  $-\text{CH}=\text{CH}-$ , and  $\text{R}_n$  is absent. The prior art indicates that the final product, or any intermediate or starting material, may be resolved by known methods, and that a racemic mixture of the product may be enzymatically converted to chirally pure compounds. The  $\gamma$ -lactam can be prepared by reacting cyclopentadiene with tosyl cyanide.

R.D. Allan et al, Eur. J. Pharmacol. 122 (1986) 339-348, disclose a series of GABA analogues, resolved and unresolved, including compounds of formula II



II

in which  $-\text{X}-$  is  $-\text{CH}_2-$ ,  $-\text{Y}-\text{Z}-$  is  $-\text{CH}=\text{CH}-$ , and  $\text{R}_1$  and  $\text{R}_2$  are H. In particular, (+)-1R,4R-4-aminocyclopent-2-ene-1-carboxylic acid is disclosed, although its activity is much lower than that of the structurally-isomeric 1-ene.

Summary of the Invention

The present invention is based on the surprising discovery of lactamases that will react with a  $\gamma$ -lactam of formula I to give a single enantiomer of the lactam and the corresponding ring-opened compound of formula II in an enantiomeric form. The enantiomers are novel compounds, and are excellent synthons for a desired enantiomer of Carbovir or a pharmacologically-active analogue.

In compounds of the invention, X is  $-\text{CH}_2-$ ,  $-(\text{CH}_2)_2-$ ,  $-\text{Q}-$ ,  $-\text{CH}_2-\text{Q}-$  or  $-\text{Q}-\text{CH}_2-$  and Q is a heteroatom (including NH); either Y or Z are independently selected from  $-\text{CH}_2-$  and a heteroatom (including NH), or  $-\text{Y}-\text{Z}-$  is  $-\text{CH}=\text{CH}-$ ,  $-\text{CH}=\text{N}-$  or  $-\text{N}=\text{CH}-$ ; and  $\text{R}_n$  is absent or represents one or more independently-selected

substituents at any available position(s) on the X,Y,Z-containing ring. R<sub>1</sub> is H or alkyl; R<sub>2</sub> is H or a blocking group.


While (+)-4-aminocyclopent-2-ene-1-carboxylic acid is known, the present invention provides a new utility, i.e. its conversion to another compound of formula II, e.g. as a synthon.

5

### Description of the Invention

Unsaturated lactams of formula I (in which -Y-Z- means -CH=CH-, -CH=N- or -N=CH-) can be prepared, by generally known means, by a Diels-Alder reaction which comprises reacting a corresponding compound of formula III

15



III


with tosyl cyanide or chlorosulphonyl isocyanate. Depending on the nature of X, the compound of formula III may variously be, for example, a cyclopentadiene, 1,3-cyclohexadiene, furan, pyrrole or 1,2-dihydropyridine.

Unsaturated lactams of formula I may be reduced to give saturated lactams of formula I, if necessary with concomitant protection of susceptible groups, by known means. The unsaturated lactams may also be utilised in the preparation of compounds of the invention bearing one or more substituents R.

R<sub>n</sub> may be any substituent or substituents which do not interfere with the lactamase reaction; examples of R (if present) are methyl, ethyl, n-butyl, OH, Cl, Br, F, CF<sub>3</sub> and azido. For example, F or another halogen may be a substituent of X, e.g. as -CHHal-. The total number of carbon atoms in the group or groups R will not usually exceed 8. n may be, for example, 1 or 2, but R<sub>n</sub> is preferably absent.

The compound of formula III is preferably a 1,3-cyclohexadiene or, most preferably, a (symmetrical) 5-membered compound. X is preferably -CH<sub>2</sub>-. Specific examples of compounds of formula I are the following:

30



45

Others are given in PCT/GB90/00574.

It is surprising that material of biological origin will react selectively with a  $\gamma$ -lactam of formula I, to give the desired products in good yield. The material is described herein, for convenience, as a lactamase.

Suitable activities are those present in certain novel wild-type isolates of the genera *Pseudomonas*, *Alcaligenes*, *Arthrobacter*, *Brevibacterium*, *Nocardia*, *Rhodococcus* and *Corynebacterium*, whilst not being limited to isolates of these genera. Selection for these activities may be conducted in the presence of compounds containing one or more N-acyl substituents. If necessary, elevated levels of activity may be produced by growth of cells in the presence of such compounds. Particular examples of suitable activity are those produced maximally active in cells of the unique strains ENZA-20 and *Rhodococcus* sp ENZA-1, the latter when cultivated in a suitable medium in the presence of N-acetyl-L-phenylalanine or N-acetyl-D,L-

65

phenylalanine.

*Rhodococcus* sp ENZA-1 was isolated from soil samples by enrichment culture in mineral salts medium containing N-acetyl-L-phenylalanine as the sole source of carbon and energy. The isolate has been deposited at the NCIMB in Aberdeen, on 17.10.89. The accession number is NCIMB 40213.

5 ENZA-20 was obtained from a sewage sample, and deposited at the NCIMB on 16.01.90. The accession number is NCIMB 40249.

Novel microorganisms have the ability to cause stereoselective formation of enantiomers of, say, 2-azabicyclo[2.2.1]hept-5-en-3-one and (-)-4-aminocyclopent-2-ene-1-carboxylic acid. The deposited microorganisms may, if desired, be subjected to conventional mutagenic/selection procedures, with a view to  
10 attaining improved effects.

The reaction of the lactam with the material having lactamase activity gives a compound of formula II which can be separated, as necessary or desired, from admixture with the unreacted lactam. If desired, the product ( $R_2 = H$ ) can be reacted with an acylating agent such as acetic anhydride, to give the corresponding compound (II:  $R_2 = \text{acyl}$ ). Other conventional N-blocking groups can be introduced as desired,  
15 examples being  $\text{CH}_2\text{Ar}$ ,  $\text{COOalk}$ ,  $\text{CONHalk}$ ,  $\text{SO}_2\text{alk}$ ,  $\text{Si(alk)}_3$ ,  $\text{CHO}$  and  $\text{COalk}$  (alk meaning alkyl in its broadest sense).

If the lactamase reaction is conducted in the presence of water,  $R_1$  is H. Alternatively, a nucleophile may be used to introduce an alkyl or other group  $R_1$  directly. For example, the nucleophile is methanol.

(-)-4-Aminocyclopent-2-ene-1 carboxylic acid and other cis compounds of formula II are often the  
20 product of the process. If desired, racemic cis amino-acid may be converted to racemic cis/trans amino-acid which is then esterified, allowing ready separation. The, say, (+)-trans ester may be isolated.

One alternative synthesis of the amino-acids (II) is by cleavage of the racemic lactam (I) with a chiral nucleophile (e.g. an amine or alcohol). The cleavage may show some enantioselectivity, and the resultant diastereoisomers can be separated by fractional crystallisation. Acid hydrolysis (if needed) liberates the free  
25 amino-acid.

A further alternative comprises enantioselective reaction on the double bond. Potential examples are

(i) asymmetric hydroboration (as pioneered by H.C. Brown)

(ii) catalytic asymmetric dihydroxylation (B. Sharpless)

(iii) binaphthyl rhodium/ruthenium-catalysed double bond displacement (Noyori; such a process is used  
30 in tonne scale menthol manufacture).

In each case, the unreacted lactam could be collected or the functional product be used to develop a route to a chiral drug.

Yet another alternative route to chiral products of the invention comprises conducting the Diels-Alder addition with a chiral Lewis acid catalyst or by using a chiral dienophile in place of tosyl cyanide.  
35 Economically, the use of a chiral catalyst is preferred. The resultant optically-enriched lactam may be subjected to the novel biotransformation process, in order to obtain a higher yield of pure (-)-lactam than may be possible from the racemate.

The optical isomers of the lactam (I) have a higher melting point than the racemate and therefore a higher lattice energy. Enantiomers may therefore be obtained by preferential crystallisation (entrainment),  
40 i.e. by seeding a supersaturated solution of racemate in a suitable solvent with pure enantiomer, such that more enantiomer is recovered than put in.

The following Examples illustrate the invention.

#### 45 Example 1

##### Preparation of Cells

*Rhodococcus* sp ENZA-1 was grown in a medium containing  $\text{KH}_2\text{PO}_4$  ( $7 \text{ g l}^{-1}$ ),  $\text{Na}_2\text{HPO}_4$  ( $2 \text{ g l}^{-1}$ ),  
50  $\text{MgSO}_4$  ( $0.4 \text{ g l}^{-1}$ ),  $\text{NaCl}$  ( $2 \text{ g l}^{-1}$ ),  $\text{CaCl}_2 \cdot 6\text{H}_2\text{O}$  ( $0.01 \text{ g l}^{-1}$ ),  $\text{FeCl}_3 \cdot 7\text{H}_2\text{O}$  ( $0.08 \text{ g l}^{-1}$ ),  $\text{ZnSO}_4 \cdot 7\text{H}_2\text{O}$  ( $0.0001 \text{ g l}^{-1}$ ),  $(\text{NH}_4)_2\text{SO}_4$  ( $2 \text{ g l}^{-1}$ ) yeast extract ( $1 \text{ g l}^{-1}$ ) and glucose ( $10 \text{ g l}^{-1}$ ). The medium was adjusted to pH 7.0 with 5M NaOH and sterilised by autoclaving at  $121^\circ \text{C}$  for 20 min. N-acetyl-L-phenyl-alanine at pH 7 was filter-sterilised and added to the cooled medium to give a final concentration of  $10 \text{ g l}^{-1}$ . The medium was  
55 distributed in 1 litre volum s within 5 litre shak flasks and 100 ml volum s within 500 ml shake flasks. A loopful from a slant of ENZA-1 was inoculated into 100 ml of the above medium and grown at  $30^\circ \text{C}$  with shaking at 200 rpm, for 24 hours. A 5 litre shake flask was then inoculated with 50 ml of the seed culture and grown under the same conditions. The whole culture was then harvested after 48 hours growth, by

centrifugation, and the cell paste was stored at  $-20^{\circ}\text{C}$  until use.

#### Preparation of Catalyst

5 Following thawing, *Rhodococcus* sp ENZA-1 cell paste (1.50 g) was suspended in phosphate buffer solution at pH 7 (0.1 M, 3.5 ml). The suspension of cells was then disrupted by sonication, to yield an essentially cell-free extract.

#### Preparation of (+)-lactam and (-)-amino-acid

10 The racemic lactam 2-azabicyclo[2.2.1]hept-5-en-3-one (218 mg, 2 mmol) was dissolved in phosphate buffer solution at pH 7 (0.1 M, 5.0 ml) and 0.5 ml of the cell-free extract was added. The resulting mixture was then inoculated at  $30^{\circ}\text{C}$  with shaking for 14 days.

#### Isolation of the (+)-lactam

20 The reaction mixture prepared above was extracted with dichloromethane (3 x 25 ml), and the organic layers were dried with anhydrous  $\text{MgSO}_4$ . Following filtration, the organic layers were concentrated by rotary evaporation at  $30^{\circ}\text{C}$  at reduced pressure, to yield a white solid (110 mg) which was fractionated by chromatography on silica (5 g) in the presence of diethyl ether as the mobile phase, to give the (+)-lactam (97 mg, 0.9 mmol; 88% e.e.).

#### Derivation of the (-)-amino-acid and Isolation of the (-)-ester/amide


25 The aqueous layer resulting from dichloromethane extraction of the reaction mixture was acidified to pH 1 with dilute HCl (1M) and then concentrated to near dryness by rotary evaporation at  $35^{\circ}\text{C}$  and reduced pressure. The resultant oil was then refluxed with benzene (25 ml) for 1 hour in a Dean-Stark apparatus to remove water. The resulting mixture was then concentrated by rotary evaporation at  $35^{\circ}\text{C}$  and reduced pressure, to yield a brown solid which was refluxed with dry methanol (25 ml) for 5 hours. The resulting solution was then filtered and evaporated to dryness at  $35^{\circ}\text{C}$  and reduced pressure. Dry pyridine (10 ml) was added, and the solution was cooled in an ice-bath. At this point, acetic anhydride (5 ml) was added dropwise with stirring, and the mixture was allowed to warm to room temperature. Following a further 2 hours stirring, the solution was concentrated by evaporation at  $35^{\circ}\text{C}$  and reduced pressure. The resulting oil was then taken up in dichloromethane (150 ml) and washed consecutively with water (30 ml), sat.  $\text{NaHCO}_3$  solution (2 x 30 ml), dilute HCl (0.1 M, 2 x 30 ml) and brine (30 ml), at which point the solution was dried over anhydrous  $\text{MgSO}_4$ . Subsequently, the solution was concentrated by evaporation under reduced pressure at  $35^{\circ}\text{C}$  and fractionated by chromatography on silica (10 g) in the presence of a mobile phase having the composition:  $\text{CH}_2\text{Cl}_2/(\text{CH}_3)_2\text{CO}$  80:20, to yield the (-)-ester/amide (II:  $\text{X} = \text{CH}_2$ ;  $\text{Y-Z} = -\text{CH}=\text{CH}-$ ;  $\text{R}_1 = \text{CH}_3$ ;  $\text{R}_2 = \text{Ac}$ ) (128 mg, 0.7 mmol; 81% e.e.).

#### Example 2

45 The procedure of Example 1 was repeated, except that isolate ENZA-20 was used. In cell preparation, growth in the presence of N-acetyl-L-phenylalanine was not necessary. The products of reaction with the racemic lactam were the (-)-lactam and the (+)-amino-acid. The (-)-lactam had >98% e.e. The (+)-ester/amide was isolated.


#### Claims

55 1. An enantiomer, substantially free of other enantiomers, of a lactam of the formula



I

- 10 wherein X is -CH<sub>2</sub>-, -(CH<sub>2</sub>)<sub>2</sub>-, -Q-, -CH<sub>2</sub>-Q- or -Q-CH<sub>2</sub>- and Q is a heteroatom (including NH); either Y and Z are independently selected from -CH<sub>2</sub>- and a heteroatom (including NH), or -Y-Z- is -CH=CH-, -CH=N- or -N=CH-; and R<sub>n</sub> is absent or represents one or more independently-selected substituents at any available position(s) on the X,Y,Z-containing ring.
- 15 2. An enantiomer, substantially free of other enantiomers, of an amino-acid or amino ester of the formula



II

- 20 wherein X, Y, Z and R<sub>n</sub> are as defined in claim 1; R<sub>1</sub> is H or alkyl; and R<sub>2</sub> is H or a N-blocking group; provided that the enantiomer is not (+)-1R,4R-4-aminocyclopent-2-ene-1-carboxylic acid.
- 25 3. An enantiomer according to claim 2, wherein R<sub>1</sub> is methyl.
4. An enantiomer according to claim 2, wherein R<sub>1</sub> is H.
5. An enantiomer according to any of claims 2 to 4, wherein R<sub>2</sub> is acetyl.
6. An enantiomer according to any of claims 2 to 4, wherein R<sub>2</sub> is H.
- 30 7. An enantiomer according to any preceding claim, wherein R<sub>n</sub> is absent.
8. An enantiomer according to any preceding claim, wherein X is -CH<sub>2</sub>-.
9. An enantiomer according to any preceding claim, wherein -Y-Z- is -CH=CH-.
10. An enantiomer according to claim 1, which is 2-azabicyclo[2.2.1]hept-5-en-3-one.
11. An enantiomer according to claim 2, which is (-)-4-aminocyclopent-2-ene-1-carboxylic acid.
- 35 12. An enzyme having lactamase activity capable of stereospecific reaction with a mixture of enantiomers of a compound of formula I as defined in any of claims 1 and 7 to 10.
13. An enzyme according to claim 12, characterised by the ability to cause stereoselective formation of an enantiomer of 2-azabicyclo[2.2.1]hept-5-en-3-one and (-) or (+)-4-aminocyclopent-2-ene-1-carboxylic acid from racemic 2-azabicyclo[2.2.1]hept-5-en-3-one.
- 40 14. A microorganism having lactamase activity as defined in claim 12 or claim 13.
15. A microorganism according to claim 14, having the characteristics of that deposited as NCIMB 40123 or NCIMB 40249, or a mutant thereof.
16. A process for preparing an enantiomer according to any of claims 1 to 11, which comprises reacting a mixture of enantiomers of the lactam of formula I with an enzyme according to claim 12 or claim 13 or a microorganism according to claim 14 or claim 15.
- 45 17. A process according to claim 16, wherein the lactam is reacted in the presence of a nucleophile, whereby the amino ester (R<sub>1</sub> is not H) is formed.
18. A process for preparing an enantiomer of formula II as defined in claim 2, wherein R<sub>1</sub> and/or R<sub>2</sub> are H, which comprises reacting the corresponding enantiomer wherein R<sub>1</sub> and R<sub>2</sub> are H with a nucleophile and/or an acylating agent or other agent capable of introducing a N-blocking group.
- 50



European  
Patent Office

## EUROPEAN SEARCH REPORT

Application Number

EP 90 31 1253

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl.5)
X	CHEMICAL ABSTRACTS, vol. 93, no. 3, 21st July 1980, page 738, abstract no. 26739t, Columbus, Ohio, US; R.D. ALLAN et al.: "Synthesis of analogs of GABA. III. All four stereoisomers of 3-aminocyclopentanecarboxylic acid and a stereochemical correlation with amidinomycin", & AUST. J. CHEM. 1979, 32(11), 2517-21 * Abstract *	2,4,6-8	C 07 D 209/52 C 07 C 233/52 C 12 N 1/00 C 12 N 9/86 C 12 P 41/00
X	CHEMICAL ABSTRACTS, vol. 91, no. 25, 17th December 1979, page 25, abstract no. 204205j, Columbus, Ohio, US; G.A.R. JOHNSTON et al.: "Stereospecific actions of GABA analogs", & ADV. PHARMACOL. THER., PROC. INT. CONGR. PHARMACOL., 7TH 1978 (Pub. 1979), 2, 11-18 * Abstract; compounds I,III,IV *	2,4,6-8	
A	TETRAHEDRON LETTERS, vol. 28, no. 17, July 1987, pages 1887-1888, Oxford, GB; S. SICSIC et al.: "Chemoenzymatic approach to carbocyclic analogues of ribonucleosides and nicotinamide ribose" * Page 1887 *	2-5,7-9	
X	EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 24, no. 4, July-August 1989, pages 415-420, Paris, FR; M. IKBAL et al.: "Synthèse des deux énantiomères de l'analogue carbocyclique du nicotinamide ribose et évaluation de leurs propriétés biologiques" * Pages 416,419 *	2-5,7-9	C 07 D 209/00 C 07 D 233/00 C 12 N 1/00 C 12 N 9/00 C 12 P 41/00
A	JOURNAL OF ORGANIC CHEMISTRY, vol. 43, no. 12, 9th June 1978, pages 2311-2320, American Chemical Society, Washington, DC, US; S. DALUGE et al.: "Synthesis of carbocyclic aminonucleosides" * Page 2311, scheme I; page 2314, right-hand column, compounds 1,2a,2b *	1-5,7-11	
The present search report has been drawn up for all claims			
Place of search		Date of completion of search	Examiner
The Hague		18 January 91	ENGLISH R.F.
<b>CATEGORY OF CITED DOCUMENTS</b> X: particularly relevant if taken alone Y: particularly relevant if combined with another document of the same category A: technological background O: non-written disclosure P: intermediate document T: theory or principle underlying the invention  E: earlier patent document, but published on, or after the filing date D: document cited in the application L: document cited for other reasons  &: member of the same patent family, corresponding document			